Search Result

Results for "

Breast tumor kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	BRK (1) Akt (12) AMPK (1) Apoptosis (18) Aryl Hydrocarbon Receptor (1) Aurora Kinase (8) Autophagy (6) Bcl-2 Family (3) Bcr-Abl (3) c-Met/HGFR (1) Cadherin (3) Casein Kinase (1) Caspase (2) Cathepsin (1) CDK (6) COX (2) Cytochrome P450 (2) Discoidin Domain Receptor (1) DNA/RNA Synthesis (1) Drug Derivative (1) Drug Metabolite (1) DYRK (1) EGFR (7) ERK (5) Estrogen Receptor/ERR (1) FAK (1) FGFR (1) FLT3 (5) Guanylate Cyclase (2) HDAC (1) Hedgehog (1) HIF/HIF Prolyl-Hydroxylase (2) IFNAR (1) IGF-1R (2) Interleukin Related (1) Isotope-Labeled Compounds (1) JAK (1) MAP4K (1) MARK (1) MEK (2) MELK (1) MMP (5) Mps1 (1) mTOR (1) NEKs (1) p38 MAPK (4) PARP (2) PDK-1 (1) PI3K (5) Pim (2) PKC (1) Polo-like Kinase (PLK) (3) Raf (4) Ras (1) Reference Standards (5) ROCK (1) SARS-CoV (1) Ser/Thr Kinase (2) SphK (1) Src (3) STAT (6) TAM Receptor (8) TGF-beta/Smad (1) TGF-β Receptor (2) VEGFR (8) YAP (1)
By Research Areas:	Cancer (57) Cardiovascular Disease (4) Endocrinology (1) Infection (3) Inflammation/Immunology (9) Metabolic Disease (3) Neurological Disease (5)

By Targets:

BRK (1)

Akt (12)

AMPK (1)

Apoptosis (18)

Aryl Hydrocarbon Receptor (1)

Aurora Kinase (8)

Autophagy (6)

Bcl-2 Family (3)

Bcr-Abl (3)

c-Met/HGFR (1)

Cadherin (3)

Casein Kinase (1)

Caspase (2)

Cathepsin (1)

CDK (6)

COX (2)

Cytochrome P450 (2)

Discoidin Domain Receptor (1)

DNA/RNA Synthesis (1)

Drug Derivative (1)

Drug Metabolite (1)

DYRK (1)

EGFR (7)

ERK (5)

Estrogen Receptor/ERR (1)

FAK (1)

FGFR (1)

FLT3 (5)

Guanylate Cyclase (2)

HDAC (1)

Hedgehog (1)

HIF/HIF Prolyl-Hydroxylase (2)

IFNAR (1)

IGF-1R (2)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

JAK (1)

MAP4K (1)

MARK (1)

MEK (2)

MELK (1)

MMP (5)

Mps1 (1)

mTOR (1)

NEKs (1)

p38 MAPK (4)

PARP (2)

PDK-1 (1)

PI3K (5)

Pim (2)

PKC (1)

Polo-like Kinase (PLK) (3)

Raf (4)

Ras (1)

Reference Standards (5)

ROCK (1)

SARS-CoV (1)

Ser/Thr Kinase (2)

SphK (1)

Src (3)

STAT (6)

TAM Receptor (8)

TGF-beta/Smad (1)

TGF-β Receptor (2)

VEGFR (8)

YAP (1)

By Research Areas:

Cancer (57)

Cardiovascular Disease (4)

Endocrinology (1)

Infection (3)

Inflammation/Immunology (9)

Metabolic Disease (3)

Neurological Disease (5)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: BRK Large Tumor Suppressor (LATS) TNF Receptor BCRP

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-10201

Sorafenib Maximum Cited Publications 283 Publications Verification Bay 43-9006	Raf VEGFR FLT3 Autophagy Apoptosis STAT Akt MMP Cadherin p38 MAPK ERK MEK PI3K PARP Bcl-2 Family	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .

HY-50895

Gefitinib 195+ Cited Publications ZD1839	EGFR Autophagy Apoptosis	Cancer
Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC₅₀ of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC₅₀ of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .

HY-15150

Bemcentinib 60+ Cited Publications R428; BGB324	TAM Receptor	Cancer
Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC₅₀ of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

HY-10201A

Sorafenib tosylate Maximum Cited Publications 283 Publications Verification Bay 43-9006 tosylate	Raf VEGFR FLT3 Autophagy Apoptosis STAT Akt MMP Cadherin p38 MAPK ERK MEK PI3K PARP Bcl-2 Family	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Sorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .

HY-P99364

Icrucumab 1 Publications Verification Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	VEGFR Apoptosis p38 MAPK Akt	Endocrinology Cancer
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer .

HY-172737

RP-1664	Polo-like Kinase (PLK)	Cancer
RP-1664 is a selective and orally active PLK4 inhibitor with an IC₅₀ of 3 nM. RP-1664 demonstrates exquisite selectivity over related kinases, including AURKA/B and PLK1. RP-1664 disrupts centriole biogenesis in cancer cells and leads an accumulation of PLK4 and p21 protein. RP-1664 demonstrates increased sensitivity in TRIM37-high-expressing cells or tumors. RP-1664 exhibits anti-tumor activity in breast cancer and neuroblastoma research ^[1][2].

HY-145601

Tinengotinib TT 00420	Aurora Kinase FGFR VEGFR	Cancer
Tinengotinib (TT00420) is an orally active, spectrally selective small molecule kinase inhibitor targeting Aurora A/B (IC₅₀=1.2-3.3 nM), FGFR1/2/3 (IC₅₀=1.5-3.5 nM), VEGFRs, JAK1/2 and CSF1R. Tinengotinib blocks Aurora kinase-mediated cell cycle progression (inducing G2/M arrest), inhibits FGFR/JNK-JUN signaling pathway and activates MEK/ERK-dependent apoptotic pathway. Tinengotinib has the activity of anti-tumor proliferation, inducing apoptosis, inhibiting angiogenesis and regulating tumor microenvironment. Tinengotinib can be used in the study of triple-negative breast cancer (TNBC), gallbladder cancer and tumor immune microenvironment .

HY-13072

Cenisertib 1 Publications Verification AS-703569; R-763	Aurora Kinase Bcr-Abl Akt STAT FLT3	Cancer
Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of *Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor* growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

HY-164129

CDK4-IN-3	CDK Apoptosis	Cancer
CDK4-IN-3 (Compound 389) is a potent irreversible cyclin-dependent kinase 4 (CDK4) inhibitor (IC₅₀=25 nM, >10-fold selective over CDK6). CDK4-IN-3 arrests the cell cycle at G₁ phase, and induces tumor cell apoptosis. CDK4-IN-3 is promising for research of solid tumors such as breast and lung cancers .

HY-W013386

LY83583 1 Publications Verification	Guanylate Cyclase	Cardiovascular Disease Neurological Disease Cancer
LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease .

HY-157396

JAB-2485	Aurora Kinase Apoptosis Caspase	Cancer
JAB-2485 is an orally active and selective Aurora kinase A (AURKA) inhibitor with an IC₅₀ value of 0.327 nM. JAB-2485 exhibits inhibitory activity against various tumor cell lines such as neuroblastoma, triple-negative breast cancer, small cell lung cancer, and epithelial ovarian cancer. JAB-2485 can induce cell cycle arrest and apoptosis in tumor cells. JAB-2485 has antitumor activity .

HY-12964

SGI-7079 3 Publications Verification	TAM Receptor	Cancer
SGI-7079 is a selective, ATP-competitive, orally active inhibitor of the *receptor tyrosine kinase* Axl. SGI-7079 blocks Axl-mediated signaling pathways such as NF-κB activation and MMP-9** expression, thereby inhibiting tumor cell proliferation, migration and invasion. SGI-7079 is mainly used in the research of malignant tumors such as inflammatory breast cancer and bladder cancer, as well as in combination with immunization (used in combination with PD-1 therapy)[1][2][3].

HY-116437

Selatinib 1 Publications Verification	EGFR	Cancer
Selatinib is an orally active EGFR and HER2 tyrosine kinase inhibitor with IC₅₀ values of 13.0 nM and 8.5 nM, respectively. Selatinib undergoes oxidative metabolism in vivo to produce Lapatinib (HY-50898). Selatinib inhibits the growth of breast, gastric and ovarian tumors. Selatinib can be used in research related to gastric cancer, breast cancer and ovarian cancer .

HY-108333

SB-633825 4 Publications Verification	Ser/Thr Kinase	Cardiovascular Disease Cancer
SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC₅₀s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis .

HY-119715

AG-012986	CDK Apoptosis	Inflammation/Immunology Cancer
AG-012986 is a pan-CDK inhibitor with K_i values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC50 values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces K_i-67 expression. AG-012986 exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .

HY-115514A

BRK inhibitor P21d hydrochloride	BRK	Cancer
BRK inhibitor P21d hydrochloride is a potent breast tumor kinase (BRK/PTK6) inhibitor with an IC₅₀ of 30 nM. BRK inhibitor P21d hydrochloride inhibits p-SAM68 with an IC₅₀ of 52 nM. BRK inhibitor P21d hydrochloride can be used to evaluate the in vivo activity of BRK inhibitors in xenograft breast tumor models .

HY-50895R

Gefitinib (Standard) ZD1839 (Standard)	Reference Standards EGFR Autophagy Apoptosis	Cancer
Gefitinib (Standard) is the analytical standard of Gefitinib. This product is intended for research and analytical applications. Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC₅₀ of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC₅₀ of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .

HY-159643

NDI-101150	MAP4K IFNAR Interleukin Related	Inflammation/Immunology Cancer
NDI-101150 is an orally active, potent and selective *hematopoietic progenitor cell kinase* 1 (HPK1) inhibitor with an IC₅₀** of 0.7 nM. NDI-101150 blocks HPK1-mediated negative regulation of immune receptor signaling, inhibits immunosuppression of T cell activation, enhances antigen-specific antibody production and augments B-cell activation. NDI-101150 inhibits tumor growth in syngeneic tumor models, establishes durable antitumor immune memory, and synergizes with anti-PD1 to enhance exhausted T cell activity and drive tumor regressions. NDI-101150 can be used for the research of cancer, such as breast cancer and colon cancer .

HY-N7694

Isotoosendanin 1 Publications Verification	TGF-β Receptor JAK STAT Apoptosis	Inflammation/Immunology Cancer
Isotoosendanin is an orally active TGFβR1 inhibitor and abrogating its kinase activity (IC₅₀ = 6732 nM). Isotoosendanin inhibits the JAK/STAT3 signaling pathway by directly targeting SHP-2, enhancing its stability, and reducing its ubiquitination. Isotoosendanin inhibits TGF-β-induced reduces the migration, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. Isotoosendanin exhibits anti-tumor efficacy in TNBC xenograft models and A549 xenograft tumors. Isotoosendanin exhibits significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema tests. Isotoosendanin can be used for the study of non-small cell lung cancer (NSCLC), TNBC and inflammation .

HY-162006

Pim-1 kinase inhibitor 8	Pim Apoptosis Autophagy	Metabolic Disease Inflammation/Immunology Cancer
Pim-1 kinase inhibitor 8 is a potent PIM-1 inhibitor with an IC₅₀ value of 14.3 nM. Pim-1 kinase inhibitor 8 impedes cell proliferation and migration through PIM-1 inhibition and the induction of both apoptosis and autophagy. Pim-1 kinase inhibitor 8 inhibits solid tumor growth in Solid Ehrlich Carcinoma (SEC)-bearing mice. Pim-1 kinase inhibitor 8 can be used for breast and liver cancer research .

HY-177332

SLC-391	TAM Receptor SARS-CoV Akt	Infection Cancer
SLC-391 is an orally active AXL kinase inhibitor with an IC₅₀ of 9.6 nM against AXL kinase. SLC-391 inhibits Gas6-induced AXL-dependent phosphorylation of Akt. SLC-391 inhibits SARS-CoV-2 infection, entry and replication in cells. SLC-391 suppresses cancer cell proliferation. SLC-391 inhibits tumor growth in mouse solid tumor xenograft models. SLC-391 can be used for the research of COVID-19, influenza virus infection, triple-negative breast cancer, chronic myeloid leukemia and non-small cell lung cancer .

HY-P991664

AG01	Src Akt ERK TAM Receptor c-Met/HGFR MMP HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
AG01 is a monoclonal antibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as Axl, c-MET, HIF-1α, and VEGF. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers .

HY-13072R

Cenisertib (Standard) AS-703569 (Standard); R-763 (Standard)	Aurora Kinase Bcr-Abl Akt STAT FLT3 Reference Standards	Cancer
Cenisertib (Standard) is the analytical standard of Cenisertib. This product is intended for research and analytical applications. Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

HY-176561

IOR-160	Casein Kinase HDAC	Cancer
IOR-160 is a dual inhibitor of *casein kinase* 2 (CK2) and HDACs. IOR-160 exhibits high selectivity for CK2 (IC₅₀ = 1.7 nM) and broad inhibitory activity against HDAC (HDAC 1, 2, 3, and 6 with IC₅₀*s of 3.3 nM, 24.0 nM, 3.9 nM, and 13.0 nM, respectively, with low activity for HDAC8). IOR-160 modulates key cellular signaling pathways by inhibiting AKT phosphorylation and increasing acetylated α-tubulin. IOR-160 inhibits tumor* growth and reduces tumor burden through dual CK2/HDAC inhibition. IOR-160 is indicated for use in triple-negative breast cancer research .

HY-158618

Aurora kinase inhibitor-14	Aurora Kinase Apoptosis	Cancer
Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of Aurora kinases with IC₅₀ values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia .

HY-177913

OSU-02067	PDK-1	Cancer
OSU-02067 is a selective 3-phosphoinositide-dependent protein kinase-1 (PDK-1) inhibitor (IC₅₀=9 μM). OSU-02067 is promising for research of solid tumors (e.g., prostate, breast, colorectal cancers) .

HY-178443

Pim-1 kinase-IN-15	Pim Apoptosis	Cancer
Pim-1 kinase-IN-15 (Compound 15) is a highly potent and selective Pim-1 kinase inhibitor (IC₅₀=0.212 μM). Pim-1 kinase-IN-15 induces tumor cell apoptosis and suppresses cell migration. Pim-1 kinase-IN-15 is promising for research of oncology, such as breast cancer .

HY-122844B

Ifebemtinib tosylate BI-853520 tosylate; IN-10018 tosylate	FAK	Cancer
Ifebemtinib (tosylate) (BI-853520 (tosylate); IN-10018 (tosylate)) is a highly selective PTK2 kinase inhibitor. Ifebemtinib (tosylate) demonstrates anti-tumor activity. Ifebemtinib (tosylate) inhibits FAK autophosphorylation in prostate carcinoma cells. Ifebemtinib (tosylate) can inhibit spheroid formation and orthotopic tumor growth in vivo. Ifebemtinib (tosylate) can be studied in anticancer research such as solid tumors, breast cancer, and malignant pleural mesothelioma .

HY-112485

(R)-FTY720-vinylphosphonate	SphK Drug Derivative	Cancer
(R)-FTY720-vinylphosphonate is a sphingosine kinase 1 (SK1) inhibitor. (R)-FTY720-ene-phosphonate is also an FTY720 analogue. (R)-FTY720-vinylphosphonate is promising for research of solid tumors like breast cancer .

HY-W013386R

LY83583 (Standard)	Reference Standards Guanylate Cyclase	Cardiovascular Disease Neurological Disease Cancer
LY83583 (Standard) is the analytical standard of LY83583 (HY-W013386). This product is intended for research and analytical applications. LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease .

HY-15150R

Bemcentinib (Standard) R428 (Standard); BGB324 (Standard)	TAM Receptor Reference Standards	Cancer
Bemcentinib (Standard) is the analytical standard of Bemcentinib. This product is intended for research and analytical applications. Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

HY-15150G

Bemcentinib (GMP) R428 (GMP); BGB324 (GMP)	TAM Receptor	Cancer
Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC₅₀ of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

HY-50895B

Gefitinib dihydrochloride ZD 1839 dihydrochloride	EGFR Autophagy Apoptosis	Cancer
Gefitinib (ZD 1839) dihydrochloride is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC₅₀ of 33 nM. Gefitinib dihydrochloride selectively inhibits EGF-stimulated tumor cell growth (IC₅₀ of 54 nM) and blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib dihydrochloride also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .

HY-13072B

Cenisertib benzoate AS-703569 benzoate; R-763 benzoate	Aurora Kinase Bcr-Abl Akt STAT FLT3	Cancer
Cenisertib (AS-703569) benzoate is an ATP-competitive multi-kinase inhibitor that blocks the activity of *Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib benzoate induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib benzoate inhibits tumor* growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

HY-178157

Multi-target kinase-IN-7	CDK EGFR VEGFR	Cancer
Multi-target kinase-IN-7 (Compound 1e) is an orally active multi-target kinase inhibitor (IC₅₀ values: CDK2=0.314 μM, EGFR=0.183 μM, HER-2=0.197 μM, VEGFR-2=0.235 μM). Multi-target kinase-IN-7 is promising for research of solid tumors (e.g., lung, breast, prostate cancer) .

HY-N15340

1-Oleoyl-2-linoleoyl-sn-glycerol	PKC	Cancer
1-Oleoyl-2-linoleoyl-sn-glycerol is a diacylglycerol (DG). 1-Oleoyl-2-linoleoyl-sn-glycerol can activate protein kinase C (PKC), thus triggering downstream signaling cascades and promoting tumor growth. 1-Oleoyl-2-linoleoyl-sn-glycerol is promising for research of breast cancer .

HY-W110138

Chloroxoquinoline	DNA/RNA Synthesis Cytochrome P450 ROCK	Cancer
Chloroxoquinoline is an anticancer agent. Chloroxoquinoline damages the DNA templates of cancer cells, inducing DNA breaks and cell death, and inhibits cell invasion via down-regulating Rho/Rho kinase signaling pathway. Chloroxoquinoline enhances the radiation sensitivity of Lewis lung cancer cells and xenograft tumors in tumor-bearing mouse models but decreases efficacy after long term exposure in rat models by auto-induction effects on CYP1A and CYP3A. Chloroxoquinoline has a broad-spectrum anticancer activity, such as non-small-cell lung carcinoma (NSCLC), breast cancer and gastric cancer .

HY-E70609

PIK3CG Recombinant Human Active Lipid Kinase	PI3K	Inflammation/Immunology Cancer
PIK3CG Recombinant Human Active Lipid Kinase belongs to PI3K enzyme family that is directly regulated by Gβγ and Ras in the G protein coupled receptor (GPCR) pathway. PIK3CG has the function of regulating cellular inflammation and immunity. PIK3CG is also a potential target for the treatment of a few malignant tumors such as acute lymphoblastic leukemia, medulloblastoma, claudin-low breast cancer (CLBC) and Kaposi sarcoma .

HY-164530

SKLB646	Src VEGFR Raf p38 MAPK	Cancer
SKLB646 is an orally active multi-target kinase inhibitor. SKLB646 shows significant inhibitory effects on SRC and VEGFR2 with IC₅₀ values ??of 0.002 μmol/L and 0.012 μmol/L, respectively. SKLB646 also shows significant inhibitory effects on B-Raf and C-Raf with IC₅₀ values ??of 0.022 μmol/L and 0.019 μmol/L, respectively. SKLB646 inhibits the activation of the SRC signaling pathway and blocks the MAPK signaling pathway by inhibiting Raf kinase. In addition, SKLB646 can inhibit the proliferation, migration and invasion of human umbilical vein endothelial cells (HUVEC) to inhibit tumor-induced angiopoietic formation. SKLB646 shows significant anti-proliferative and anti-survival activities against triple-negative breast cancer (TNBC) cell lines .

HY-167854

KW-2450 free base	Aurora Kinase Apoptosis IGF-1R	Cancer
KW-2450 Free base is a potent multikinase inhibitor targeting Aurora A and B kinases, demonstrating significant antitumor activity against triple-negative breast cancer (TNBC). KW-2450 Free base effectively reduces cell viability, promotes apoptosis, and inhibits colony formation and mammosphere formation in TNBC cells. KW-2450 Free base significantly suppresses the growth of TNBC xenografts, leading to tetraploid accumulation followed by apoptosis or the survival of octaploid cells. KW-2450 Free base enhances the efficacy of combination therapy with the MEK inhibitor selumetinib, resulting in a synergistic antitumor effect in TNBC models. KW-2450 Free base also acts as an orally bioavailable inhibitor of IGF-1R and IR tyrosine kinases, contributing to its potential antineoplastic activity by inhibiting tumor cell proliferation and inducing apoptosis.

HY-181082

Aurora kinase-IN-10	Aurora Kinase	Cancer
Aurora kinase-IN-10 is an Aurora kinase inhibitor. Aurora kinase-IN-10 exhibits IC₅₀ values of 5.94 nM and 86.06 nM against Aurora A and Aurora B, respectively. Aurora kinase-IN-10 has anti-tumor activity and can be used in the research of tumors such as triple-negative breast cancer .

HY-N17632

Moracin G	Estrogen Receptor/ERR Akt MELK COX Apoptosis	Inflammation/Immunology Cancer
Moracin G is a plant-derived kinase modulator and receptor ligand that forms stable bindings with multiple key proteins (AKT1, COX2 and Estrogen receptor 1) and competitively inhibits the activity of specific kinases. By binding to MELK to disrupt cell cycle regulation, Moracin G impairs the survival and proliferation of cancer cells, induces cancer cell apoptosis, and thereby exerts anti-tumor potential. Moracin G can be used in research related to periodontitis and breast cancer .

HY-179439

Multi-kinase-IN-8	COX VEGFR HIF/HIF Prolyl-Hydroxylase Caspase Bcl-2 Family Apoptosis MMP	Cancer
Multi-kinase-IN-8 is a muti-kinase inhibitor. Multi-kinase-IN-8 inhibits COX-1 (IC₅₀ of 12.6 μM), COX-2 (IC₅₀ of 0.05 μM) and VEGFR-2 (IC₅₀ of 0.12 nM). Multi-kinase-IN-8 inhibits tumor-associated carbonic anhydrases (CA IX and CA XII with K_i of 31.5 nM and 386.9 nM, respectively). Multi-kinase-IN-8 triggers cell cycle arrest and apoptosis through upregulation of Caspase 9 and Bax along with downregulation of Bcl 2. Multi-kinase-IN-8 suppresses PGE2, p-VEGFR-2, MMP-9 and HIF-1α and exhibits growth-inhibitory activity against breast cancer, lung cancer, and colorectal adenocarcinoma .

HY-182614

BJ-2302	Src Cathepsin PI3K Akt Ras Raf ERK MMP	Cancer
BJ-2302 is a Src kinase inhibitor with an IC₅₀ of 3.23 μM, and inhibits cathepsin S (CTSS) activity .BJ-2302 binds to Src, suppresses PI3K/AKT and Ras/Raf/ERK pathways, and reduces CTSS and MMP-9 expression .BJ-2302 inhibits cancer cell invasion, metastasis, proliferation, and tumor growth .BJ-2302 does not induce cytotoxicity in normal breast epithelial cells .BJ-2302 can be used for the research of breast cancer and triple-negative breast cancer .

HY-177957

CDK2-IN-52	CDK	Cancer
CDK2-IN-52 (Compound Cpb No 39) is a selective cyclin-dependent kinase 2 (CDK2) inhibitor with a DC₅₀ value of 1-10 nM. CDK2-IN-52 induces cell cycle arrest and suppresses tumor cell proliferation. CDK2-IN-52 is promising for research of CDK2-overexpressing malignancies such as breast and ovarian cancers .

HY-108333R

SB-633825 (Standard)	Ser/Thr Kinase Reference Standards	Cardiovascular Disease Cancer
SB-633825 (Standard) is the analytical standard of SB-633825 (HY-108333). This product is intended for research and analytical applications. SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC₅₀s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis .

HY-181051

PLK1-IN-16	Polo-like Kinase (PLK) Apoptosis	Cancer
PLK1-IN-16 is a selective polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.25 nM. PLK1-IN-16 exhibits lower inhibitory potency against PLK2 and PLK3, induces G2 phase cell cycle arrest, induces apoptosis, and exhibits antiproliferative activity against tumor cells. PLK1-IN-16 can be stable under simulated gastric acid environmental conditions, and acceptable CYP 450 inhibition. PLK1-IN-16 can be used for the study of triple-negative breast cancer (TNBC), breast cancer, leukemia .

HY-182743

OICR19451	AMPK MARK YAP	Cancer
OICR19451 is an orally active dual NUAK1/NUAK2 and MARK2/MARK3 kinase inhibitor, with IC₅₀ values of 12 nM and 10 nM against NUAK1 and NUAK2, and 101 nM and 124 nM against MARK2 and MARK3, respectively. OICR19451 modulates the Hippo signaling pathway, increases the phosphorylation level of YAP, enhances the cytoplasmic localization of YAP/TAZ, and inhibits the expression of oncogenes. OICR19451 inhibits cancer cell growth, reduces metastasis, promotes tumor capsule formation, and improves mouse survival in an orthotopic breast cancer model. OICR19451 can be used for research related to triple-negative breast cancer .

HY-182470

AG-012986 dihydrochloride	CDK
AG-012986 (dihydrochloride) is a pan-CDK inhibitor with K_i values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC₅₀ values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 (dihydrochloride) causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 (dihydrochloride) induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces K_i-67 expression. AG-012986 (dihydrochloride) exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 (dihydrochloride) can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .

HY-15150S

Bemcentinib-d8 R428-d₈; BGB324-d₈	Isotope-Labeled Compounds TAM Receptor	Cancer
Bemcentinib-d₈ (R428-d₈) is the deuterium labeled Bemcentinib (HY-15150). Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC₅₀ of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

Cat. No.	상품명	Type

HY-15150G

Bemcentinib (GMP)

R428 (GMP); BGB324 (GMP)

Fluorescent Dyes

Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC₅₀ of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

Cat. No.	상품명	Type

HY-15150G

Bemcentinib (GMP)

R428 (GMP); BGB324 (GMP)

Biochemical Assay Reagents

Cat. No.	상품명	Target	Research Area	Image

HY-P99364

Icrucumab 1 Publications Verification Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	VEGFR Apoptosis p38 MAPK Akt	Endocrinology Cancer
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer .

HY-P991664

AG01	Src Akt ERK TAM Receptor c-Met/HGFR MMP HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
AG01 is a monoclonal antibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as Axl, c-MET, HIF-1α, and VEGF. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers .

Cat. No.	상품명	Category	Target	Chemical Structure

HY-N7694

Isotoosendanin 1 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Melia toosendan Sieb. et Zucc. Plants Meliaceae Inflammation/Immunology Disease Research Fields Source Classification	TGF-β Receptor JAK STAT Apoptosis
Isotoosendanin is an orally active TGFβR1 inhibitor and abrogating its kinase activity (IC₅₀ = 6732 nM). Isotoosendanin inhibits the JAK/STAT3 signaling pathway by directly targeting SHP-2, enhancing its stability, and reducing its ubiquitination. Isotoosendanin inhibits TGF-β-induced reduces the migration, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. Isotoosendanin exhibits anti-tumor efficacy in TNBC xenograft models and A549 xenograft tumors. Isotoosendanin exhibits significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema tests. Isotoosendanin can be used for the study of non-small cell lung cancer (NSCLC), TNBC and inflammation .

HY-N15340

1-Oleoyl-2-linoleoyl-sn-glycerol	Natural Products Endogenous metabolite Source Classification	PKC
1-Oleoyl-2-linoleoyl-sn-glycerol is a diacylglycerol (DG). 1-Oleoyl-2-linoleoyl-sn-glycerol can activate protein kinase C (PKC), thus triggering downstream signaling cascades and promoting tumor growth. 1-Oleoyl-2-linoleoyl-sn-glycerol is promising for research of breast cancer .

HY-N17632

Moracin G	Structural Classification Phenols Polyphenols Plants Moraceae Morus alba Linn. Source Classification	Estrogen Receptor/ERR Akt MELK COX Apoptosis
Moracin G is a plant-derived kinase modulator and receptor ligand that forms stable bindings with multiple key proteins (AKT1, COX2 and Estrogen receptor 1) and competitively inhibits the activity of specific kinases. By binding to MELK to disrupt cell cycle regulation, Moracin G impairs the survival and proliferation of cancer cells, induces cancer cell apoptosis, and thereby exerts anti-tumor potential. Moracin G can be used in research related to periodontitis and breast cancer .

Recombinant Proteins Recommended:

Breast Tumor Kinase

Species:	Human (3) Mouse (1)
Tag:	His (2) Tag Free (1) GST (3)
Source:	Sf9 insect cells (4)

Cat. No.	Compare	상품명	Species	Source	Image

HY-P702726

	Brk/PTK6 Protein, Human (Active, sf9, His, GST) PTK6; PTK6 protein tyrosine kinase 6; protein-tyrosine kinase 6; BRK; Breast tumor kinase; protein-tyrosine kinase BRK; tyrosine-protein kinase BRK; FLJ42088;	Human	Sf9 insect cells
	Brk is a nonreceptor tyrosine protein kinase that regulates signaling pathways critical for epithelial tissue differentiation, normal maintenance, and tumor growth. Context-dependent functions involve a variety of substrates, including RNA-binding proteins, transcription factors, and signaling molecules. Brk/PTK6 Protein, Human (sf9, His, GST) is the recombinant human-derived Brk/PTK6, expressed by Sf9 insect cells, with His, GST labeled tag. The total length of Brk/PTK6 Protein, Human (sf9, His, GST) is 450 a.a..

HY-P701706

	AURKA Protein, Human (Inactive, sf9) AURKA; Aurora kinase A; Aurora 2; Aurora/IPL1-related kinase 1; ARK-1; Aurora-related kinase 1; hARK1; Breast tumor-amplified kinase; Serine/threonine-protein kinase 15; Serine/threonine-protein kinase 6; Serine/threonine-protein kinase aurora-A	Human	Sf9 insect cells

HY-P72856

	Brk Protein, Mouse (Active, sf9, His-GST) Protein-tyrosine kinase 6; SRC-related intestinal kinase; Ptk6; Sik	Mouse	Sf9 insect cells
	Brk protein is a non-receptor tyrosine protein kinase that regulates signaling pathways critical for epithelial differentiation and tumor growth.Its context-dependent functions involve phosphorylating substrates such as RNA-binding proteins, transcription factors, and signaling molecules.Brk Protein, Mouse (sf9, His-GST) is the recombinant mouse-derived Brk protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P75470

	Brk/PTK6 Protein, Human (sf9, GST) Protein-tyrosine kinase 6; SRC-related intestinal kinase; Ptk6; Sik	Human	Sf9 insect cells
	Brk is a nonreceptor tyrosine protein kinase that regulates signaling pathways critical for epithelial tissue differentiation, normal maintenance, and tumor growth. Context-dependent functions involve a variety of substrates, including RNA-binding proteins, transcription factors, and signaling molecules. Brk/PTK6 Protein, Human (sf9, GST) is the recombinant human-derived Brk protein, expressed by Sf9 insect cells , with N-GST labeled tag.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

Cat. No.	상품명	Chemical Structure

HY-15150S

Bemcentinib-d8

Bemcentinib-d₈ (R428-d₈) is the deuterium labeled Bemcentinib (HY-15150). Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC₅₀ of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

Host:	Mouse (1) Rabbit (3)
Reactivity:	Human (4)
Application:	IHC-P (3) ICC/IF (1) IP (1) WB (2) ELISA (2)
Isotype:	IgG (3)
Conjugation:	Non-conjugated (4)
Clonality:	Monoclonal (3) Recombinant (1)
Modification:	Unmodified (3)

Cat. No.	Compare	상품명	Application	Reactivity	Image

HY-P85066

	Brk/PTK6 Antibody (YA4758) PTK6; BRK; Protein-tyrosine kinase 6; Breast tumor kinase; Tyrosine-protein kinase BRK	WB, ELISA	Human
	Brk/PTK6 Antibody (YA4758) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Brk/PTK6.

HY-P81458

	Brk/PTK6 Antibody (YA1203) PTK6; BRK; Protein-tyrosine kinase 6; Breast tumor kinase; Tyrosine-protein kinase BRK	IHC-P	Human
	Brk/PTK6 Antibody (YA1203) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Brk/PTK6.

HY-P81458A

	Brk/PTK6 Antibody (YA1203)(PBS only) PTK6; BRK; Protein-tyrosine kinase 6; Breast tumor kinase; Tyrosine-protein kinase BRK	IHC-P	Human
	Brk/PTK6 Antibody (YA1203) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Brk/PTK6.

HY-P86641

	Aurora A Antibody (YA6333) Aurora kinase A; Aurora 2; Aurora/IPL1-related kinase 1; ARK-1; Aurora-related kinase 1; hARK1; Breast tumor-amplified kinase; Serine/threonine-protein kinase 15; Serine/threonine-protein kinase 6; Serine/threonine-protein kinase aurora-A;	WB, IHC-P, ICC/IF, IP, ELISA	Human
	Aurora A Antibody (YA6333) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Aurora A.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

Breast tumor kinase

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products